Evidence map›Paper›PMID 26614912›Full record

ArticleBiotechnology and bioengineering2016

The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines.

Jacob J Elmer, Matthew D Christensen, Sutapa Barua, Jennifer Lehrman, Karmella A Haynes, Kaushal Rege

Abstract read
In one paragraph

Article in Biotechnology and bioengineering, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. An inhibitor screen identifies histone-modifying enzymes as mediators of polymer-mediated transgene expression from plasmid DNA.Journal of controlled release : official journal of the Controlled Release Society · 2018
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jacob J Elmer *Chemical Engineering, Arizona State University, Tempe, Arizona 85287.
Matthew D Christensen *Chemical Engineering, Arizona State University, Tempe, Arizona 85287.
Sutapa BaruaChemical Engineering, Arizona State University, Tempe, Arizona 85287.
Jennifer LehrmanHarrington Biomedical Engineering, Arizona State University, Tempe, Arizona.
Karmella A HaynesHarrington Biomedical Engineering, Arizona State University, Tempe, Arizona.
Kaushal RegeChemical Engineering, Arizona State University, Tempe, Arizona 85287.
Arizona State University · US

Funding

Engineering DNA Delivery Polymers using Combinatorial and Cheminformatics MethodsR01GM093229 · NIGMS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI REGE, KAUSHAL · 2011 to 2015
$1.5M
Synthetic chromatin for cancer researchK01CA188164 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI HAYNES, KARMELLA ANN · 2014 to 2016
$474k
NCI NIH HHS K01 CA188164NIGMS NIH HHS R01 GM093229
6 · The paper itself

Abstract

Eukaryotic cells maintain an immense amount of genetic information by tightly wrapping their DNA around positively charged histones. While this strategy allows human cells to maintain more than 25,000 genes, histone binding can also block gene expression. Consequently, cells express histone acetyl transferases (HATs) to acetylate histone lysines and release DNA for transcription. Conversely, histone deacetylases (HDACs) are employed for restoring the positive charge on the histones, thereby silencing gene expression by increasing histone-DNA binding. It has previously been shown that histones bind and silence viral DNA, while hyperacetylation of histones via HDAC inhibition restores viral gene expression. In this study, we demonstrate that treatment with Entinostat, an HDAC inhibitor, enhances transgene (luciferase) expression by up to 25-fold in human prostate and murine bladder cancer cell lines when used with cationic polymers for plasmid DNA delivery. Entinostat treatment altered cell cycle progression, resulting in a significant increase in the fraction of cells present in the G0/G1 phase at low micromolar concentrations. While this moderate G0/G1 arrest disappeared at higher concentrations, a modest increase in the fraction of apoptotic cells and a decrease in cell proliferation were observed, consistent with the known anticancer effects of the drug. DNase accessibility studies revealed no significant change in plasmid transcriptional availability with Entinostat treatment. However, quantitative PCR studies indicated that Entinostat treatment, at the optimal dose for enhancing transgene expression, led to an increase in the amount of plasmid present in the nucleus in two cancer cell lines. Taken together, our results show that Entinostat enhances polymer- mediated transgene expression and can be useful in applications related to transient protein expression in mammalian cells. Biotechnol. Bioeng. 2016;113: 1345-1356. © 2015 Wiley Periodicals, Inc.

Indexed as

BenzamidesCell Line, TumorDNA, NeoplasmGene Expression Regulation, EnzymologicHistone Deacetylase InhibitorsHistone DeacetylasesHumansNeoplasms, ExperimentalPyridinesTransgenesUp-RegulationBenzamidesDNA, NeoplasmentinostatHistone Deacetylase InhibitorsHistone DeacetylasesPyridinesacetylationepigenetic silencinghistonesnon-viral gene deliverytransient protein expression

Identifiers

PMID26614912
PMCPMC5140276
OpenAlexW2262543291

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.